Moderna Posts Interim Data From mRNA Triplet Program In Solid Tumors

Moderna Inc MRNA announced interim data from Phase 1 study of mRNA-2752 (Triplet) in patients with accessible solid tumors and lymphomas.
The data showed that the mRNA Triplet program given in combination with AstraZeneca Plc's AZN Imfinzi (durvalumab) was tolerated at all dose levels and elicited evidence of anti-tumor activity.
The recommended dose for expansion (RDE) is up to 8mg mRNA-2752 + durvalumab.
The data were presented at the Society for Immunotherapy of Cancer's (SITC) Annual Meeting.
The study consists of dose escalation and dose confirmation parts, which will occur in Arm A and Arm B, followed by a dose expansion part, which will occur in Arm B, and a Dose Exploration in Arm C as neoadjuvant therapy for cutaneous melanoma.
Enrollment in the dose-expansion part of Arm B and Arm C is currently ongoing.
Price Action: MRNA shares are down 0.42% at $230.22 during the premarket session on the last check Monday.